nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.06.2014 | Original Article

Variants of 11β-hydroxysteroid dehydrogenase (HSD11B) gene type 1 and 2 in Chinese obese adolescents

verfasst von: Li Li Ruan, Jun Xu, Chun Lin Wang, Chao Chun Zou

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the relationship between 11β-hydroxysteroid dehydrogenase (HSD11B) gene type 1 and 2 and obesity in Chinese children.

Methods

A total of 400 obese and 200 healthy adolescents were enrolled as obese and control groups. Seven SNPs in HSD11B1 (rs4393158, rs2235543, rs10082248, rs10863782, rs2236903, rs2298930, rs4545339) and four variants in HSD11B2 gene (rs28934592, rs28934591, rs28934594 and rs28934593) were measured by automated platform MassArray.

Results

The rs28934592 in HSD11B2 and rs10863782 in HSD11B1 were excluded as false positive or HWE P < 0.05. Moreover, one allele type was found in the other three locations of HSD11B2. The minor allele frequency of rs2235543 and rs10082248 was higher in patients than that in controls (P = 0.045, P = 0.041, respectively). The rs10082248, rs2298930 and rs4545339 were associated with the risk of obesity in the recessive model (P < 0.05, respectively). Moreover, the total cholesterol in patients with GG or AG genotype was significantly higher than that in patients with AA genotype in rs10082248. The rs4393158 was associated with the hypertension in log-additive model test (P = 0.037), and glucose abnormal and hypercholesteremia in dominant model test (P < 0.05, respectively), while the rs2235543 was associated with hypercholesteremia in overdominant model test (P = 0.017).

Conclusions

The polymorphism of HSD11B1 may be a cause of childhood obesity, or even associated with the complication of childhood obesity. However, variants of HSD11B2 may be not a cause of obesity.

Wyrwoll CS, Holmes MC, Seckl JR (2011) 11beta-Hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 32:265–286PubMedCentralPubMedCrossRef

Tomlinson JW, Walker EA, Bujalska IJ et al (2004) 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831–866PubMedCrossRef

Schipper L, Spee B, Rothuizen J et al (2004) Characterisation of 11 beta-hydroxysteroid dehydrogenases in feline kidney and liver. Biochim Biophys Acta 1688:68–77PubMedCrossRef

Seckl JR, Holmes MC (2007) Mechanisms of disease: glucocorticoids, their placental metabolism and fetal ‘programming’ of adult pathophysiology. Nat Clin Pract Endocrinol Metab 3:479–488PubMedCrossRef

Seckl JR, Meaney MJ (2004) Glucocorticoid programming. Ann N Y Acad Sci 1032:63–84PubMedCrossRef

Inder WJ, Obeyesekere VR, Alford FP et al (2011) Skeletal muscle 11betaHSD1 activity of nondiabetic subjects is unaltered in central obesity-associated insulin resistance. Horm Metab Res 6:e16674

Sjostrand M, Jansson PA, Palming J et al (2010) Repeated measurements of 11beta-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects–no change following a mixed meal. Horm Metab Res 42:798–802PubMedCrossRef

Stimson RH, Walker BR (2007) Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol 32:141–159PubMed

Miyamoto Y, Morisaki H, Yamanaka I et al (2009) Association study of 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in urban Japanese cohort. Diabetes Res Clin Pract 85:132–138PubMedCrossRef

10.

Nair S, Lee YH, Lindsay RS et al (2004) 11beta-hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47:1088–1095PubMedCrossRef

11.

Plourde M, Samson C, Durocher F et al (2008) Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. J Steroid Biochem Mol Biol 109:115–128PubMedCrossRef

12.

Coeli FB, Ferraz LF, Lemos-Marini SH et al (2008) Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p. R186C in the HSD11B2 gene. Arq Bras Endocrinol Metab 52:1277–1281CrossRef

13.

Atanasov AG, Ignatova ID, Nashev LG et al (2007) Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol 18:1262–1270PubMedCrossRef

14.

Bailey MA, Craigie E, Livingstone DE et al (2011) Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure. Hypertension 57:515–520PubMedCrossRef

15.

Manning JR, Bailey MA, Soares DC et al (2010) In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence. Physiol Genomics 42:319–330PubMedCentralPubMedCrossRef

16.

Ferrari P (2010) The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 1802:1178–1187PubMedCrossRef

17.

Kamide K, Kokubo Y, Hanada H et al (2006) Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens Res 29:243–252PubMedCrossRef

18.

Williams TA, Mulatero P, Filigheddu F et al (2005) Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney Int 67:631–637PubMedCrossRef

19.

Meas T, Carreira E, Wang Y et al (2010) 11beta-hydroxysteroid dehydrogenase type 1 of the subcutaneous adipose tissue is dysregulated but not associated with metabolic disorders in adults born small for gestational age. J Clin Endocrinol Metab 95:3949–3954PubMedCrossRef

20.

Hwang JY, Lee SH, Kim GS et al (2009) HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone 45:1098–1103PubMedCrossRef

21.

Caramelli E, Strippoli P, Di Giacomi T et al (2001) Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity. Endocr Res 27:47–61PubMedCrossRef

22.

Feigelson HS, Teras LR, Diver WR et al (2008) Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the cancer prevention study II. Breast Cancer Res 10:R57PubMedCentralPubMedCrossRef

23.

Shimodaira M, Nakayama T, Sato I et al (2013) Glucocorticoid synthesis-related genes: HSD11B1 and HSD11B2 in hypertensive disorders in pregnancy. Gynecol Endocrinol 29:657–661PubMedCrossRef

24.

Ter-Minassian M, Asomaning K, Zhao Y et al (2012) Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Int J Cancer 130:1338–1346

25.

Rogoff D, Smolenicka Z, Bergada I et al (1998) The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. J Clin Endocrinol Metab 83:4391–4393PubMed

26.

Kitanaka S, Katsumata N, Tanae A et al (1997) A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 82:4054–4058PubMed

27.

Li A, Tedde R, Krozowski ZS et al (1998) Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet 63:370–379PubMedCentralPubMedCrossRef

28.

Ku YH, Koo BK, Kwak SH et al (2009) Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene. Horm Res 72:25–32PubMedCrossRef

29.

Staab CA, Stegk JP, Haenisch S et al (2011) Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. Chem Biol Interact 191:104–112PubMedCrossRef

30.

Bruley C, Lyons V, Worsley AG et al (2006) A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent. Endocrinology 147:2879–2885PubMedCrossRef

31.

Malavasi EL, Kelly V, Nath N et al (2010) Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels. Endocrinology 151:195–202PubMedCentralPubMedCrossRef

32.

Li G, Hernandez-Ono A, Crooke RM et al (2011) Effects of antisense-mediated inhibition of 11beta-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res 52:971–981PubMedCentralPubMedCrossRef

33.

Tzschoppe A, Fahlbusch F, Seidel J et al (2011) Dexamethasone stimulates the expression of leptin and 11beta-HSD2 in primary human placental trophoblastic cells. Eur J Obstet Gynecol Reprod Biol 156:50–55PubMedCrossRef

34.

Huang Y, Li X, Lin H et al (2010) Regulation of 11beta-hydroxysteroid dehydrogenase 1 and 2 by IGF-1 in mice. Biochem Biophys Res Commun 391:1752–1756PubMedCrossRef

35.

Vackova Z, Vagnerova K, Libra A et al (2009) Dexamethasone and betamethasone administration during pregnancy affects expression and function of 11 beta-hydroxysteroid dehydrogenase type 2 in the rat placenta. Reprod Toxicol 28:46–51PubMedCrossRef

36.

Sharma A, Guan H, Yang K (2009) The p38 mitogen-activated protein kinase regulates 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) expression in human trophoblast cells through modulation of 11beta-HSD2 messenger ribonucleic acid stability. Endocrinology 150:4278–4286PubMedCrossRef

37.

Balazs Z, Schweizer RA, Frey FJ et al (2008) DHEA induces 11 -HSD2 by acting on CCAAT/enhancer-binding proteins. J Am Soc Nephrol 19:92–101PubMedCentralPubMedCrossRef

38.

Krall P, Carvajal C, Ortiz E et al (2007) Urinary free cortisol is not a biochemical marker of hypertension. Am J Hypertens 20:459–465PubMedCrossRef

39.

Glowka FK, Kosicka K, Karazniewicz-Lada M (2010) HPLC method for determination of fluorescence derivatives of cortisol, cortisone and their tetrahydro- and allo-tetrahydro-metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 878:283–289PubMedCrossRef

Titel: Variants of 11β-hydroxysteroid dehydrogenase (HSD11B) gene type 1 and 2 in Chinese obese adolescents
verfasst von: Li Li Ruan
Jun Xu
Chun Lin Wang
Chao Chun Zou
Publikationsdatum: 01.06.2014
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 6/2014
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-014-0075-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Justification of anthropometric empirical indicator (AEI) by digital chest and pelvic X-rays: a comparative scenario with DXA on obesity grounds

Serum 25 hydroxyvitamin D in employees of a Middle Eastern university hospital

Italian consensus for the classification and reporting of thyroid cytology

Role of protein kinase C β2 in relaxin-mediated inhibition of cardiac fibrosis

Serum-negative autoimmune thyroiditis: what’s in a name?